Where does Grifols Therapeutics Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Grifols Therapeutics Inc. ranks #26,411 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Grifols Therapeutics Inc. hold?

Grifols Therapeutics Inc. holds 10 US utility patents granted between 2015 and 2018, spanning 7 technology areas.

What is Grifols Therapeutics Inc.'s Innovation Score?

Grifols Therapeutics Inc. has an Innovation Score of 23.6 out of 100 (12th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Grifols Therapeutics Inc.'s patent grant rate increasing or decreasing?

Grifols Therapeutics Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Grifols Therapeutics Inc.'s patents?

Grifols Therapeutics Inc.'s patents average 9.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Grifols Therapeutics Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Grifols Therapeutics Inc.

Q: What technology areas does Grifols Therapeutics Inc. focus on?

Grifols Therapeutics Inc.'s top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 5 patents, ranking #840 of 2,502 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Grifols ranks #26,411 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 7 technology areas.

#26,411
of 49,997 US assignees by volume: 12th percentile
by Innovation Score (23.6/100): 9.9
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26411 · US Corporation #26,411 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,411/49,997
PHOTO-FINISH Grasslanz Technology
CPC-NARROW C12Q · 7 areas
INNOV-THIN 23.6/100
CLAIMS-PAR 9.9 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Grasslanz Technology Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Grifols’s 23.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (35%) Velocity 0.0 pts (0%) Breadth 9.4 pts (40%) Claim depth 5.9 pts (25%)

Qualcomm Incorporated · highest

85
Focal Jmlab · near

24
Grifols Therapeutics · this assignee

24
Picote Solutions · near

24
Tuf-tite · near

24
Bluebonnet Foods · near

24
3D Lighting… · lowest

7

What this shows Grifols's Innovation Score is 23.6/100 (12th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Grifols?

Each dot is one of Grifols’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Grifols’s own 9.9 claims/patent is at or below the 16.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Grifols vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Grifols's grants concentrate

Grifols Therapeutics Inc. is a focused PatentsView assignee: 7 CPC subclasses with 50% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2016 (3 grants) versus a trough of 2 in 2015. By volume, Grifols sits between Grasslanz Technology Limited and Guardhat, Inc..

Grasslanz Technol…

10
Green Bay Packagi…

10
Greenonyx

10
Greyfin

10
Gritstone Bio

10
Groundspeak

10
Guangzhou Lianrou…

10
Guardhat

10
Grifols Therapeut… ◀

10

What this shows Grifols holds 10 patents at rank #26,417, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Grifols

By rank, the assignees closest to #26,417 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Grifols's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Grifols, neither rank-band nor same-CPC leaders (those blocks stay above). In C12Q (Measuring OR Testing Processes Involving Enzymes), Grifols ranks #840 of 2,502 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (24 here).

Tuf-tite, Inc. 24 Picote Solutions Inc. 24 Focal Jmlab 24 Bluebonnet Foods, L.P. 24

Grifols's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 12th percentile higher than 12% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Grifols Therapeutics Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	20.0%
2016	3	30.0%
2017	2	20.0%
2018	3	30.0%

Which technologies does Grifols Therapeutics Inc. patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C12Y - Enzymes 2

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

C07K - Peptides 2

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Grifols Therapeutics Inc.'s patent record in context - here's where to go next.

Grifols Therapeutics Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 50% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #26,411 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Grifols Therapeutics Inc. against Grasslanz Technology Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 23.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.